PUBLIC COMPANY
save$CTMXCytomX Therapeutics, Inc.
$CTMX3.5700+5.31%South San Francisco, CA, USupdated 18h ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Phase 1
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1First In Human Study of CX-2051 in Advanced Solid Tumors
- phase1First In Human Study of CX-801 in Advanced Solid Tumors
- phase2PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
- phase1A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors
- phase2PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
- phase2Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
- phase2PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL
- phase2PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
Insider activity
source: SEC Form 4🐶 Hiring Signal
next earnings Nov 5, 2026
News
- STAT+: Up and down the ladder: The latest comings and goingsFrom new hires to departures, promotions, and hires, here are the latest comings and goings in the pharma industry.stat · 27d ago
Data sources
last refreshed 31m ago
Found something off?
comments(0)
5-min edit window · permanent after that